On Oct. 5, 2026, Medical device maker GE HealthCare said it would buy privately held Sofie Biosciences for $945 million in ​cash, in a move that strengthens its ability ‌to manufacture and distribute PET imaging drugs.

The acquisition will give GE HealthCare US rights to FAPI-74, an experimental PET imaging agent in ​late-stage testing that could be used to detect several ​types of cancer. GE HealthCare already owns rights ⁠to the product outside the US.

Here are more details:

• The ​deal bolsters GE HealthCare’s pharmaceutical diagnostics arm by adding products ​used with its imaging systems and increasing its exposure to the growing radiopharmaceuticals market
• It comes after Curium in August struck a deal of up ​to $8 billion for radiopharma peer Lantheus, underscoring rising dealmaking ​in the industry as firms seek to capitalize on the growing use ‌of ⁠radioactive drugs in cancer care
• GE HealthCare’s radiopharma business includes Flyrcado, a PET imaging agent approved by the US FDA for detecting coronary artery disease, myocardial ischemia and heart attacks
• The ​company bought Montreal-based ​medical imaging ⁠software provider Intelerad in a $2.3 billion takeover in March, expanding its outpatient care reach
• It said Sofie ​would continue to manufacture products for existing customers, ​including ⁠other radiopharma companies, after the transaction closes, which is expected in the first half of 2027
• Sofie Biosciences, owned by private ⁠equity ​firm Trilantic, develops products including radioisotopes ​used in PET scans. It also operates facilities that make and distribute them ​for hospitals and imaging centers